Beyond Cellular Models: Longevica Capitalizes on World’s Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan Pipeline
Longevica Therapeutics, a biotechnology company bridging the translation gap between empirical geroscience and human therapeutics, today announced the formation of its Scientific Advisory Board (SAB). Featuring globally recognized leaders spanning cell signaling, computational phenomics, multi-omics, quantitative pharmacology, medicinal chemistry, clinical trial execution, and biopharma venture capital, the multidisciplinary assembly marks Longevica’s operational pivot from foundational discovery and data generation to clinical execution, drug development, and strategic alliance building.
